(NASDAQ: PCRX) Pacira Biosciences's forecast annual revenue growth rate of 8.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Pacira Biosciences's revenue in 2025 is $700,966,000.On average, 6 Wall Street analysts forecast PCRX's revenue for 2025 to be $34,696,537,215, with the lowest PCRX revenue forecast at $34,261,077,787, and the highest PCRX revenue forecast at $35,860,384,676. On average, 6 Wall Street analysts forecast PCRX's revenue for 2026 to be $38,420,525,157, with the lowest PCRX revenue forecast at $36,244,477,476, and the highest PCRX revenue forecast at $42,594,966,028.
In 2027, PCRX is forecast to generate $41,706,230,820 in revenue, with the lowest revenue forecast at $37,719,764,039 and the highest revenue forecast at $47,839,452,421.